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Bis-Picolinamide ruthenium (III) dihalide complexes: dichloride to 
diiodide exchange generates single trans isomers with high 
potency and cancer cell selectivity 
Aida M. Basri,[a] Rianne M. Lord,[b] Simon J. Allison,c Andrea Rodríguez-Bárzano,[a] Stephanie J. 
Lucas,[a] Felix D. Janeway,[a] Helena J. Shepherd,[d] Christopher M. Pask,[a] Roger M. Phillips[c] and 
Patrick C. McGowan[a]* 
Abstract: A library of new bis-picolinamide ruthenium(III) dihalide 
complexes of the type RuX2L2 (X = Cl or I and L = picolinamide) 
have been synthesised and characterised. They exhibit different 
picolinamide ligand binding modes, whereby one ligand is bound 
(N,N) and the other bound (N,O). Structural studies reveal a mixture 
of cis and trans isomers for the RuCl2L2 complexes but upon a halide 
exchange reaction to RuI2L2, only single trans isomers are present. 
High cytotoxic activity against human cancer cell lines was observed, 
with potencies for some complexes similar to or better than cisplatin. 
Conversion to RuI2L2 substantially increased activity towards cancer 
cell lines by >12-fold. The RuI2L2 complexes displayed potent activity 
against the A2780cis (cisplatin-resistant human ovarian cancer) cell 
line, with >4-fold higher potency than cisplatin. Equitoxic activity was 
observed against normoxic and hypoxic cancer cells, indicating the 
potential to eradicate both the hypoxic and aerobic fractions of solid 
tumours with similar efficiency. Selected complexes were also tested 
against non-cancer ARPE-19 cells. The RuI2L2 complexes are more 
potent than the RuCl2L2 analogues, and also more selective towards 
cancer cells with a selectivity factor >7-fold. 
Introduction 
The use of trans dihalide ancillary ligands in the design of new 
anti-cancer drugs, based on the structure of transplatin, has 
received little attention for many years, due to early studies 
showing the trans-Pt complexes to be inactive due to high 
kinetic instability.[1] However, in recent years, examples of active 
trans-Pt anti-cancer complexes (Figure 1) have been 
reported.[2–9] In 1993, Coluccia et al. substituted the ammine in 
both cisplatin (a) and transplatin (b), for imino ether substituents 
and showed the trans geometry (c) to have the greatest in vitro 
cytotoxicity against P388 leukemia cells.[2] Kelland et al. showed 
that addition of a benzene ring to transplatin resulted in a trans 
complex, JM335 (d), that is >3-fold more active than its cis 
analogue.[4] Unlike transplatin, JM335 produced an increase in 
inter-strand crosslinking with an increase in drug concentration. 
Farrell et al. synthesised compounds of the type trans-[PtL2Cl2] 
(e) and showed they are as active as cisplatin against a range of 
cell lines and are dramatically more active than transplatin.[10] 
More recently, Sadler et al. reported a trans-Pt(N3)2(OH)2(Py)2 
complex (f) which is photo-activated by visible light at 420 nm, 
and is more potent upon light irradiation.[9]  
Figure 1 Previously reported trans-Pt complexes a-f 
Ruthenium-based complexes are some of the most promising 
anti-cancer drugs, with reported selective potency in vitro and in 
vivo (Figure 2).[11,12] However, there has been a lack of suitable 
trans ruthenium derivatives due to the propensity of the 
molecules to undergo isomerisation. The first reported cytotoxic 
trans-ruthenium complexes were KP1019 (g)[13–15] and NAMI-A 
(h),[16–19] which in Phase I clinical trials were well tolerated 
showing only limited side effects.[20,21] NAMI-A has also 
undergone Phase II clinical studies in combination with 
gemcitabine, however, this combination had some adverse 
toxicity and failed to show any improvement in results compared 
to gemcitabine treatment alone.[22,23] The activity of NAMI-A is 
likely to involve multiple mechanisms. At a physiological pH of 
7.4 it can undergo hydrolysis leading to release of chloride and 
DMSO and the formation of a number of potentially active 
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species.[19,24–26] The activity of NAMI-A is also influenced by its 
redox status. Reduction of NAMI-A strongly depends on pH and 
is accelerated on increasing the pH resulting in the generation of 
active Ru(II) product(s).[27] Amongst potential intracellular targets, 
reduced NAMI-A binds human serum albumin.[28] Unlike cisplatin, 
DNA is not the main pharmacological target for NAMI-A, 
although it has been reported that this complex can bind to DNA 
and inhibit DNA replication in vitro.[29,30] KP1019 is thought to be 
reduced in vivo to an active Ru(II) species and also offers a 
different mode of action to cisplatin, with increased 
selectivity.[21,31] KP1019, like NAMI-A, also reacts with human 
serum proteins, including human albumin and transferrin.[32,33] 
KP1339 (i), the sodium salt of KP1019, has better solubility that 
KP1019[34,35] and has shown promising results in both Phase I 
and II clinical trial.[36,37] More recently new ruthenium-nitrosyl 
complexes of the type (H2ind)[RuCl4(NO)(Hind)] (j) were 
reported, in which both the cis and trans isomers exhibit time-
dependent responses against human cancer cell lines.[38,39] with 
the trans-isomer displaying higher anti-proliferative activity than 
the analogous cis-isomer. 
Figure 2 Previously reported trans-ruthenium complexes g-j 
Ruthenium complexes of the type RuX2L2 (X = halide, and L = 
bidentate ligand) were seen previously to undergo isomerisation, 
giving rise to six different structural geometries (Figure 3), this 
includes the cis-cis-cis enantiomer.[40] Reedijk et al. have 
reported the anti-cancer activities of Ru(azpy)2Cl2 complexes 
with differences in their activities due to different structural 
isomers. The trans geometries were found to have very low 
cytotoxicity against a series of cancer cell lines.[41,42] More 
recently, Glazer et al. has compared the activities of cis-
Ru(bpy)2Cl2 with trans-Ru(qpy)Cl2, showing the trans isomer to 
be 7-10 times more active than the cis.[43] This propensity for the 
formation of different isomers is one of the reasons that there 
has been much effort dedicated to the synthesis and 
development of transition metal based candidates that are 
based on the molecular architecture associated with M-arene,[44–
51] MCp*,[47,52–57] and ferrocene derivatives.[58,59] 
Figure 3 Possible structural isomers for ruthenium complexes of the type 
RuX2L2; enantiomers for cis-cis-cis structure are also shown. 
The complexation of ruthenium with picolinamide ligands is of 
interest because of its relevance to previously reported metal-ion 
peptide chemistry, and the possibility of different ligand binding 
modes that can potentially alter the biological activity of the 
complexes.[60–68] These ligands are able to bind to the metal 
center either via the monoanionic (N,N) or (N,O) donors through 
loss of the amide proton, or as neutral (N,O) donors.[68,69] 
Different coordination modes of metal functionalised amide 
complexes have been shown to affect the activity towards 
cancer cells.[70–72] The different coordination modes of 
picolinamide derivatives have also been shown to dramatically 
affect the potencies of the compound.[50] The (N,N) bound 
complexes undergo rapid hydrolysis, bind with guanine and are 
cytotoxic to cancer cells, whereas the (N,O) bound complexes 
showed low activity and undergo slow hydrolysis. Herein we 
report on the synthesis and evaluation of a library of new 
ruthenium complexes of the type RuX2L2 (X = Cl or I, and L = 
bidentate functionalised picolinamide ligands), whereby one 
ligand coordinates (N,N) and the second ligand coordinates 
(N,O) to the ruthenium metal center. The synthesis of such 
complexes follows a known synthetic procedure by Chan et 
al.,[73] in which  the complex 6 reported here was assessed as a 
potential catalyst for the epoxidation of cyclic alkenes. 
Bhattacharya et al. has also synthesised similar complexes 
consisting of one or three picolinamide (L) ligands, 
[Ru(L)(PPh3)(H)(CO)] and [Ru(L)3] respectively with the ligands 
all bound (N,N) to the ruthenium metal center.[68,74]. We report on 
halide exchange reactions to yield the bis iodide complexes, 
[RuI2(L)2], which give single trans isomers, thus potentially 
minimising any future drug formulation issues due to the 
presence of multiple isomers with different effects or potency. 
These complexes have been measured in both solid state and 
solution in order to identify the potential isomers present. The 
trans isomers show surprisingly high cytotoxicity, with IC50 
values in the nanomolar range, and high selectivity towards 
cancer cells. 
Results and Discussion 
Synthesis of Bis-Picolinamide Ruthenium(III) Dihalide 
Complexes 
The picolinamide ligands were synthesised via a known 
literature preparation, from picolinic acid and a functionalised 
aniline.58 Compounds 1-16 were prepared by reacting 
RuCl3.3H2O with two equivalents of functionalised picolinamide 
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ligand and heating at reflux for 2 hours in ethanol, in the 
presence of one equivalent of triethylamine (Scheme 1a). 
Complex 6 has previously been reported by Chan et al.[73] and 
was synthesised for pairwise comparison with its diiodide 
analogue, and to complete our library of RuX2L2 structures. 
Compounds 17-31 were synthesised by a halide-exchange 
reaction of the ruthenium dichloride complexes with an excess of 
KI, by refluxing in ethanol overnight (Scheme 1b).[75,76] We have 
analysed the IR spectra of the picolinamide ligand precursors 
and the ruthenium dihalide complexes, which also verified 
successful complex synthesis. The spectra show CO and NH 
stretches for the ligand precursor at ~1690 cm-1 and ~3300 cm-1 
respectively. Upon complexation, these peaks were shifted to 
lower wavenumbers of ~1590 cm-1 and ~3060 cm-1 respectively, 
for both the RuCl2L2 and RuI2L2 complexes. Magnetic 
susceptibility measurements also confirmed all the ruthenium 
dihalide complexes to be in the +3 oxidation state and low-spin 
d5 with one unpaired electron (µeff = 1.60-2.53 µB). 
Structural Characterisation 
Six structural isomers are possible for complexes of the type 
RuX2L2, as shown in Figure 3.
[77] The RuCl2L2 complexes gave 
red single crystals from vapor diffusion of pentane into methanol 
or hexane into methanol, and black/green single crystals for the 
RuI2L2 complexes which were obtained from vapor diffusion of 
diethyl ether into DMF. The molecular structures for RuCl2L2 
complexes 1, 3, 5-7, 9, 11-13 and 15-16, and for RuI2L2 
complexes 18, 19, 28 and 29, as determined by X-ray 
crystallography, are presented in Figure 4a-b and Figure 5 
respectively. Complex 6 was previously reported as the cis(X)-
cis(N,N)-trans(N,O) conformer,[73] however, here we crystallised 
the complex as the cis(X)-cis(N,N)-cis(N,O) conformer. Selected 
bond lengths and angles are stated in Tables 1 and 2 for 
RuCl2L2 complexes and Table 3 for RuI2L2 complexes. The X-
ray crystallography data is detailed in the Tables S3-S5 
(Supplementary Information). The picolinamide ligands bind to 
the ruthenium metal center in a (N,N) and (N,O) bidentate 
fashion, as confirmed by their crystal structures, giving a 
ruthenium complex with a +3 oxidation state. Upon 
recrystallisation of complexes 1, 7 and 16, different crystal 
morphologies were observed in the crystallisation vials. X-ray 
crystallographic analysis of the different morphologies confirmed 
that these complexes co-crystallise as a mixture of isomers, and 
their structures are shown in Figures 4a and 4b Three different 
types of structural isomer were observed for the RuCl2L2 
complexes, the cis(X)-cis(N,N)-cis(N,O) (1a, 6, 7a and 12), 
cis(X)-trans(N,N)-cis(N,O) (15 and 16a) and trans(X)-trans(N,N)-
trans(N,O) (1b, 3, 5, 7b, 9, 11, 13 and 16b) arrangements. Due 
to the larger ionic radius of iodine and potential structural 
constraints around the ruthenium metal center posed by this, we 
hypothesised that the ruthenium iodide complexes might lead to 
fewer structural isomers than their dichloride analogues 
(Scheme 1). Indeed, the crystal structures of RuI2L2 complexes 
18, 19, 28 and 29 revealed a stable trans(X)-trans(N,N)-
trans(N,O) (Figure 5). The bis-picolinamide ruthenium dihalide 
complexes have typical M-X bond lengths and bond angles 
which are characteristic of a distorted octahedral geometry 
(Table 1 and 2 for RuCl2L2 and Table 3 for RuI2L2). 
Scheme 1 Synthetic pathways of a) RuCl2L2 and b) RuI2L2 complexes, showing the yields for different R and X substituents. 
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Figure 4a Molecular structures of RuCl2L2 complexes 1a, 6, 7a and 12 showing cis(X)-cis(N,N)-cis(N,O) arrangements and 15 and 16a showing cis(X)-trans(N,N)-
cis(N,O) arrangements. Hydrogen atoms and solvent molecules are omitted for clarity and displacement ellipsoids are at the 50% probability level (shown only for 
the heteroatoms).  
Figure 4b Molecular structures of RuCl2L2 complexes 1
b
, 3, 5, 7
b
, 9, 11, 13 and 16
b
 all showing trans(X)-trans(N,N)-trans(N,O) arrangements. Hydrogen atoms 
and solvent molecules are omitted for clarity and displacement ellipsoids are at the 50% probability level (shown only for the heteroatoms). 
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Table 1 Bond lengths (Å) and bond angles (°) for RuCl2L2 cis(X)-cis(N,N)-cis(N,O) complexes 1
a
, 6, 7
a
 and 12, and cis(X)-trans(N,N)-cis(N,O) complexes 15-16
a
 
Bond length (Å) 1
a
 6 7
a
 12 15 16
a
 
Ru1-Cl1 2.3540(9)/ 2.345(2) 2.3594(6) 2.3505(7) 2.3462(10) 2.3241(13) 
Ru1-Cl2 2.3769(9) 2.381(3) 2.3848(5) 2.3833(7) 2.3943(10) 2.3600(13) 
Ru1-N1 2.018(3) 2.030(8) 2.0510(15) 2.053(2) 2.089(3) 2.045(4) 
Ru1-N2 1.997(3) 2.013(8) 2.0270(14) 2.029(2) 2.052(3) 2.030(4) 
Ru1-N3 2.045(3) 2.071(8) 2.0741(16) 2.080(2) 2.096(3) 2.060(4) 
Ru1-O2 2.087(3) 2.091(7) 2.1089(12) 2.1043(17) 2.113(2) 2.056(3) 
Bond angle (°) 1
a
 6 7
a
 12 15 16
a
 
Cl1-Ru1-Cl2 96.16(3) 95.39(9) 95.033(19) 95.57(2) 94.71(4) 92.54(5) 
N1-Ru1-O2 175.63(10) 176.8(3) 177.80(6) 178.36(8) 98.88(10) 93.55(14) 
N2-Ru1-O2 96.34(11) 97.1(3) 98.13(5) 98.69(8) 85.17(10) 91.98(14) 
N2-Ru1-N3 86.23(11) 87.7(3) 88.07(6) 87.81(8) 97.05(11) 94.94(15) 
N1-Ru1-N3 98.72(11) 100.8(3) 100.49(6) 102.07(8) 175.62(11) 171.69(15) 
Table 2 Bond lengths (Å) and bond angles (°) for RuCl2L2 trans(X)-trans(N,N)-trans(N,O) complexes 1
b
, 3, 5, 7
b
, 9, 11, 13 and 16
b
 
Bond length (Å) 1
b
 3 5 7b 9 11 13 16
b
 
Ru1-Cl1 2.3408(14) 2.3318(10) 2.3328(9) 2.3355(9) 2.3543(6) 2.3452(9) 2.3397(13) 2.330(4) 
Ru1-Cl2 2.3498(13) 2.3533(10) 2.3664(9) 2.3362(9) 2.3767(5) 2.3914(8) 2.3425(14) 2.352(3) 
Ru1-N1 2.037(4) 1.999(3) 2.036(3) 2.033(3) 2.0514(15) 2.056(3) 2.039(4) 2.023(13) 
Ru1-N2 2.008(4) 2.036(3) 2.027(3) 2.006(3) 2.0273(15) 2.036(3) 1.996(4) 2.016(10) 
Ru1-N3 2.102(4) 2.113(3) 2.102(3) 2.106(3) 2.1219(15) 2.106(3) 2.089(4) 2.067(12) 
Ru1-O2 2.067(3) 2.087(3) 2.077(2) 2.061(2) 2.1056(13) 2.095(2) 2.100(4) 2.116(9) 
Bond angle (°) 1
b
 3 5 7b 9 11 13 16
b
 
Cl1-Ru1 Cl2 175.93(5) 176.60(5) 176.80(3) 174.66(3) 173.54(18) 174.27(3) 176.59(5) 173.82(13) 
N1-Ru1-O2 96.51(16) 97.82(16) 95.46(11) 96.70(10) 96.08(6) 96.76(10) 97.83(16) 98.3(4) 
N2-Ru1-O2 175.18(16) 176.38(16) 174.21(10) 175.10(10) 175.25(6) 174.07(10) 176.41(16) 176.3(5) 
N2-Ru1-N3 106.92(16) 105.90(18) 107.74(11) 107.74(11) 106.95(6) 106.13(11) 105.86(18) 104.6(5) 
N1-Ru1-N3 174.22(16) 175.45(18) 173.36(11) 173.84(10) 173.80(6) 174.43(11) 175.47(18) 175.8(5) 
Powder X-ray Diffraction 
Powder diffraction studies were carried out on both RuCl2L2 and 
RuI2L2 compounds, using both the bulk sample and single 
crystals. The diffractogram obtained for the RuCl2L2 complex 7 
was overlaid with both the simulated cis and simulated trans 
geometries, and shows that in the bulk sample, multiple isomers 
are present (Figure 6), which correlated well with the observed 
multiple morphologies in the crystallisation vials.  
Powder diffraction studies on the RuI2L2 complex 18 for both 
simulated and single crystals were analysed and show the bulk 
powder sample contains only a single stable trans geometry 
(Figure 7, black). This result is consistent with the crystal 
morphology observed in the crystallization vial, whereby only 
trans isomers of the RuI2L2 complexes were isolated. The 
simulated pattern for the trans geometry is the same as the 
single crystal structure and indicates that the RuI2L2 complex 
only exists as a single trans geometry in solid-state. 
Complex isomerisation during the formulation of drugs is a key 
issue as different isomers can potentially have different 
therapeutic effects, single isomer synthesis is therefore very 
important. The PXRD results indicate we can synthesise the 
RuI2L2 complexes as single trans isomers thereby satisfying this 
key requirement, and highlighting the potential progression of 
compound towards further clinical trials. 
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Figure 5 Molecular structures of RuI2L2 complexes 18, 19 and 28 showing trans(X)-trans(N,N)-trans(N,O) arrangements and 29 showing a trans-cis-cis 
arrangement. Hydrogen atoms and solvent molecules are omitted for clarity and displacement ellipsoids are at the 50% probability level (shown only for the 
heteroatoms). 
Table 3 Bond lengths (Å) for RuI2L2 trans(X)-trans(N,N)-trans(N,O) complexes 18, 19, 28 and 29 
Bond length 
(Å) 
18 19 28 29 
Ru1-I1 2.6507(17) 2.6589(8) 2.701(4) 2.664(11) 
Ru1-I2 2.6670(18) 2.7149(8) 2.703(4) 2.685(11) 
Ru1-N1 2.031(13) 2.051(6) 2.065(3) 2.039(7) 
Ru1-N2 2.009(11) 2.021(6) 2.023(3) 2.023(7) 
Ru1-N3 2.123(12) 2.119(6) 2.122(3) 2.118(7) 
Ru1-O2 2.106(10) 2.089(5) 2.092(3) 2.066(6) 
Bond angle (°) 18 19 28 29 
I1-Ru1-I2 174.89(6) 177.93(3) 174.3 (14) 174.1(4) 
N1-Ru1-O2 97.1(4) 96.6(2) 96.85(12) 174.9(3) 
N2-Ru1-O2 175.4(5) 174.3(2) 175.56(13) 96.2(3) 
N2-Ru1-N3 107.2(5) 107.4(2) 107.41(12) 171.6(3) 
N1-Ru1-N3 173.7(5) 173.7(2) 173.65(13) 108.0(3) 
 
Figure 6 Powder X-ray diffractograms for RuCl2L2 complex 7, showing 
simulated cis or trans geometry (red and black) and experimental data (blue). 
Cell Line Chemosensitivity Studies 
The bis-picolinamide ruthenium(III) dihalide complexes were 
tested for their cytotoxicity against three human cancer cell lines, 
A2780 (human ovarian cancer), A2780cis (cisplatin- resistant 
human ovarian cancer) and HT-29 (human colorectal cancer). 
Figure 7 Powder X-ray diffractograms of RuI2L2 complex 18 showing 
simulated trans geometry (blue) and experimental data (black). 
To assess selectivity towards cancer cells, cytotoxicity towards 
an epithelial non-cancer cell line (ARPE-19) was also 
determined. The IC50 values for these compounds and cisplatin, 
which is in clinical use for treatment of human ovarian cancer, 
are shown in Table 4. 
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Table 4 Response of A2780, A278cis, HT-20 and ARPE-19 cell lines to complexes 1-31 and cisplatin. Each value represents the mean (± standard deviation) of 
at least 3 independent experiments. 
 IC50 values / μM ± SD 
Compound A2780 A2780cis HT-29 ARPE-19 
Cisplatin 1.4 ± 0.3 11 ± 0.6 2.8 ± 0.3 5.97 ± 0.95
[15e]
 
X = Cl X = I X = Cl X = I X = Cl X = I X = Cl X = I X = Cl X = I 
1 17 24 ± 2 5.4 ± 0.5 47 ± 3.0 5.3 ± 0.2 23.0 ± 0.4 5.5 ± 0.4  2.8 ± 0.2 
2 18 13 ± 1 13.0 ± 0.6 21 ± 1.8 31 ± 2 6.2 ± 0.4 13.0 ± 0.9   
3 19 6.9 ± 0.8 3.4 ± 0.1 35 ± 3 12.0 ± 0.5 17 ± 1 8.4 ± 0.3 17.9 ± 0.1 6.3 ± 0.3 
4 20 22 ± 1 14 ± 1 25.0 ± 0.6 13.0 ± 0.4 7.3 ± 0.4 8.5 ± 0.7 30 ± 2 26 ± 4 
5 21 45 ± 2 16.0 ± 0.3 93 ± 2 15 ± 1 20 ± 1 14 ± 2   
6 22 21.0 ± 0.4 7.2 ± 0.1 33 ± 1 22 ± 2 11.0 ± 0.5 10 ± 1   
7 23 3.6 ± 0.2 2.8 ± 0.3 6.7 ± 0.1 3.2 ± 0.1 3.0 ± 0.1 2.3 ± 0.1   
8 24 9.2 ± 0.4 2.5 ± 0.2 4.4 ± 0.4 2.4 ± 0.2 2.8 ± 0.3 0.9 ± 0.1 2.53 ± 0.01 3.42 ± 0.04 
9 25 41.0 ± 0.7 6.6 ± 0.6 55 ± 2 4.3 ± 0.3 9.7 ± 0.3 3.4 ± 0.3 59 ± 3 11 ± 2 
10 26 31.0 ± 0.9 10.0 ± 0.4 24 ± 2 12.0 ± 0.4 11.0 ± 0.9 6.5 ±0.3   
11 27 18 ± 2 11.0 ± 0.6 37 ± 1 40 ± 2 8.3 ± 0.3 24 ± 2   
12 28 3.3 ± 0.2 2.0 ± 0.2 6.0 ± 0.4 3.3 ± 0.1 3.3 ± 0.2 1.5 ± 0.1   
13 29 7.5 ± 0.3 2.3 ± 0.2 12.0 ± 0.9 2.9 ± 0.2 6.8 ± 0.3 0.8 ± 0.1 4.85 ± 0.05 2.34 ± 0.02 
14 30 18.0 ± 0.8 6.7 ± 0.3 26 ± 1 6.6 ± 0.3 7.7 ± 0.3 4.3 ± 0.2 37 ± 7 34 ± 4 
15 31 20 ± 2 11.0 ± 0.6 22 ± 2 7.6 ± 0.3 10.0 ± 0.6 4.9 ± 0.4   
Against A2780 cancer cells, the unsubstituted picolinamide 
ruthenium dichloride complex 1 was found to be moderately 
active with an IC50 value of 24 ± 1.6 µM. Addition of a substituent 
to the phenyl ring of the picolinamide ligands generally 
increased potency especially when a substituent was placed in 
the meta or para position (Table 4, complexes 3, 7, 8, 12, 13, 23, 
24, 28 and 29). The most active ruthenium dichloride complex 
against A2780 cells was complex 12, which has a bromide 
substituent in the meta position on the phenyl ring of the 
picolinamide ligand, with an IC50 value of 3.3 ± 0.2 µM, 
comparable with that of cisplatin (1.4 ± 0.3 µM). The least active 
is complex 5 which has a 2’,5’-difluoro substituent  and only a 
moderate IC50 value of 45 ± 2 µM. A similar trend for the 
ruthenium dichloride complexes was observed against the 
cisplatin-resistant A2780cis cancer cell line with the exception of 
fluoride substituents, where ortho-fluoro (2) was more active 
than para-fluoro (3). Complexes 7, 8 and 12, which were 
amongst the most active ruthenium dichloride complexes 
against the A2780 cancer cells, were all more active than 
cisplatin against A2780cis cancer cells, with IC50 values of 6.7 ± 
0.1 µM, 4.4 ± 0.4 µM and 6.0 ± 0.4 µM respectively, compared to 
an IC50 value of 11.0 ± 0.6 µM for cisplatin (p < 0.01, for 
complexes 7, 8 and 12 compared to cisplatin). Interestingly, 
para-chloro complex 8 was ~2-fold more cytotoxic (p < 0.01) 
towards the cisplatin-resistant A2780cis cancer cells than the 
A2780 cisplatin-sensitive cells (Figure 8).  
In addition to complex 8, complex 10 and ruthenium diiodide 
complexes 25 and 31 were also more active towards the 
cisplatin-resistant cells than the parental cisplatin-sensitive 
A2780 cells (Figure 8). Furthermore, many of the ruthenium 
diiodide complexes were equally active against A2780 and 
A2780cis cells (complexes 17, 20, 21, 24 and 30) than the 
corresponding ruthenium dichloride complexes (Figure 8). 
There are currently only a few organometallic complexes that 
have been shown to overcome mechanisms of cisplatin 
resistance in cancer cells.[78–80] These results suggest that these 
complexes may be able to circumvent cisplatin resistance 
mechanisms in ovarian cancer cells,[81–84] which is a critical goal 
in developing new organometallic complexes with high cytotoxic 
activity against cancer cell lines.  
Against HT-29 cells, complexes 1, 7, 12, and 13 showed very 
similar activity to that observed against the A2780 cancer cells. 
However, the majority of ruthenium dichloride complexes were 
significantly more active against HT-29 cells. For example, 
complex 9 showed poor activity against A2780 cells (IC50 = 41.0 
± 0.7 µM) but was approximately 4-fold more active (p < 0.01) 
against HT-29 cells (IC50 = 9.7 ± 0.3 µM). Further studies are 
required but this suggests that some of the complexes may have 
preferential activity towards certain cancer cell types. The least 
active complex against HT-29 cells was unsubstituted complex 1, 
with the addition of a para or meta substituent on the phenyl ring 
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of the picolinamide ligand, the compounds generally increase in 
cytotoxicity. 
Figure 8 Response of A2780 and A2780cis cells to complexes 1-31 and 
cisplatin. The results are expressed as the resistance factor defined as the 
ratio of the mean IC50 for A2780cis divided by the mean IC50 for A2780 cells. 
Values > 1 indicate that the complex is less cytotoxic towards A2780cis cells 
than A2780 parental cells whereas values = 1 indicate that complexes are as 
active against A2780 and A2780cis cells. Values < 1 indicate that complexes 
are preferentially active against cisplatin resistant A2780cis cells 
The effects of converting ruthenium dichloride to diiodide were 
also compared for each of the fifteen different picolinamide 
complexes (Table 4). Unexpectedly, replacement of ruthenium 
dichloride with diiodide resulted in remarkably higher potency for 
most of the complexes and this was observed against all three 
human cancer cell lines tested (Figure 9). The ruthenium 
dichloride complex 9 (R = 2’,4’-Cl) is one of the least cytotoxic in 
the series, and substitution of dichloride with diiodide increases 
the IC50 values >12-fold. Against cisplatin-resistant A2780cis 
cancer cells, over half of the diiodide complexes were more 
active than cisplatin. In particular, compounds 23, 24, 28 and 29, 
were particularly potent with IC50 values of 2.4-3.3 µM compared 
to 11 µM for cisplatin. Against all three cancer cell lines, diiodide 
complexes 24 (4’-Cl) and 29 (4’-Br) were highly potent with >4-
fold higher cytotoxicity against the A2780cis cancer cells than 
cisplatin, and show nanomolar potency towards HT-29 cancer 
cells (Table 4).  
Selectivity Towards Cancer Cells 
A major limitation of many existing anti-cancer drugs is poor 
selectivity towards cancer cells. This restricts the drug dosage 
that can be used and thus effectiveness of treatment, as well as 
resulting in harmful side effects for the patient. Here we have 
Figure 9 Bar-chart showing the decrease in IC50 values and an increase in 
potency against A2780, A2780cis and HT-29 cell lines, on conversion from the 
ruthenium dichloride to the diiodide complex (1 vs 17; 4 vs 20; 5 vs 21; 9 vs 25 
and 14 vs 30). The broken lines represent Cl/ I pairs of compounds. 
compared the responses of cancer cells and non-cancer ARPE-
19 cells, to a subset of the complexes to obtain a preliminary 
indication of their cancer selectivity (Figure 10; complexes 3, 4, 
8, 9, 13, 14, 17, 19, 20, 24, 25, 29 and 30). The results are 
expressed as the selectivity index defined as the ratio of the 
mean IC50 for the normal ARPE-19 cells (Table 4) divided by the 
mean IC50 for each individual cancer cell line tested Table 4) 
with values > 1 indicating selectivity for cancer cells in vitro.  
Strikingly, with the exception of complex 3 versus complex 19, a 
general trend was seen whereby the ruthenium diiodide 
complexes showed increased cancer selectivity than their 
dichloride analogues as well as higher potency. The effects of 
ruthenium dichloride versus diiodide (compare paired 
compounds, 3 vs 19; 4 vs 20; 8 vs 24; 9 vs 25; 13 vs 29 and 14 
vs 30) and other substitutions on selectivity are shown in Figure 
10 (top panel X = Cl versus bottom panel X = I). Ruthenium 
dichloride complexes 8 and 13 and unsubstituted ruthenium 
diiodide complex 17 were more cytotoxic towards the non-
cancer ARPE-19 cells than towards the three cancer cell lines 
as indicated by selectivity ratios <1. In contrast, ruthenium 
dichloride complexes 4, 9, and 14 and ruthenium diiodide 
complexes 20, 24, 25, 29 and 30 all showed good cancer 
selectivity with selectivity indices against HT-29 cancer cells 
ranging from 2.8-fold up to 7.8-fold. Ruthenium diiodide 
complexes 20, 25 and 30 showed good selectivity towards the 
cisplatin-resistant A2780 cancer cells, with selectivity ranging 
from 2 to 5-fold increased chemosensitivity towards the cisplatin- 
resistant cancer cells compared to that for the healthy non-
cancer cells. 
When comparing the ruthenium diiodide (X = I) and ruthenium 
dichloride (X = Cl) complexes, on substituting R = 4’-F/Cl/Br with 
R = 2’,4’-diF/diCl/diBr a general reduction in potency towards the 
cancer cell lines was observed (Table 4). However, interestingly, 
these substitutions reduced activity towards the non-cancer 
ARPE-19 cells to a greater extent. The consequence of this is 
that substitution of R = 4’-F/Cl/Br with R = 2’,4’-diF/diCl/diBr (3 
vs 4; 8 vs 9; 13 vs 14; 19 vs 20; 24 vs 25 and 29 vs 30) 
generally increased cancer cell selectivity as indicated by a 
higher selectivity index (Figure 10). For example, complex 30 
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with a 2’,4’-dibromo substitution showed 2.8 to 6.3-fold higher 
cancer selectivity against all cell lines compared to 4’-bromo 
substituted complex 29 (Figure 10). 
Figure 10 Response of human cancer cell lines compared to non-cancerous 
ARPE-19 cells. The results are expressed in terms of a selectivity index 
defined as the ratio of mean IC50 values for ARPE-19 cells divided by the IC50 
for each tumour cell line. Values >1 indicate that complexes are selectivity 
cytotoxic to cancer cells as opposed to ARPE-19 cells. 
Based upon their potency, selective activity and lack of cross 
resistance with cisplatin, diiodide complexes 25 and 30 
appeared particularly promising as potential lead compounds 
and were further analysed for their activity with very short 
cellular exposure times (Table S7, Supplementary Information). 
Whilst complexes 25 and 30 showed very similar activity against 
HT29 cells with 5 days continuous exposure (3.4 vs 4.3µM), 
notable differences were observed with short drug exposure 
times. With 1, 3 and 6 hours drug exposure times, complex 30 
was consistently the more active with an IC50 of 30 µM for 1h 
exposure decreasing to 20 µM for 6 h exposure compared to an 
IC50 of 49 µM for complex 25. Whilst there are number of 
possible reasons for these differences, this indicates the need 
for future further pharmacological evaluation of the most 
promising compounds. 
Chemosensitivity Under Hypoxic Conditions 
Due to poor and chaotic tumour vasculature, a proportion of the 
cancer cells within a solid tumour are in a hypoxic (low oxygen) 
environment.[85] These cancer cells are typically more resistant 
to chemotherapy[86] and there is a pressing need for new anti-
cancer drugs whose activity is not adversely affected by 
hypoxia.[85,87] To assess the impact of hypoxia on the potency of 
these novel bis-picolinamide ruthenium complexes, the 
cytotoxicity of several of the complexes were compared for HT-
29 colorectal cancer cells growing under normal oxygen 
conditions versus under hypoxia (0.1% O2). The two most potent 
ruthenium dichloride (7, 12) and diiodide (24, 29) complexes 
were selected activity assess towards cells in hypoxic conditions. 
Table 5 shows the normoxic and hypoxic IC50 values against 
HT-29 cells for complexes 7, 12, 24 and 29, along with, 
tirapazamine (TPZ), a hypoxia-activated drug,[88] which was 
used to validate the hypoxic conditions. As expected, TPZ was 
significantly more active under hypoxic conditions than normoxia. 
All four of the dihalide complexes tested retained their potency 
under hypoxic conditions with very similar activity observed 
under normoxic and hypoxic conditions. For complexes 24 and 
29 a slight increase in IC50 values up to 1.3 µM was observed 
but this was found to be statistically insignificant (p > 0.05). 
Whilst none of the complexes showed preferential activity 
towards hypoxic cells, importantly, the equitoxic activity 
observed indicates that these complexes could potentially be 
used to target both the hypoxic and aerobic fractions of solid 
tumours with similar efficiency. 
Table 5 Response of HT-20 cells to compounds 7, 12, 24, 29 and TPZ, under 
normoxic and hypoxic conditions.  
Compound 
IC50 values / μM ± SD 
Normoxia, 21% 
O2 level 
Hypoxia, 0.1% O2 
level 
Hypoxic cytotoxicity 
ratio 
Tirapazamine 33.0 ± 2.0 2.8 ± 0.4 11.8 
Cisplatin 2.8 ± 0.1 2.4 ± 0.3 1.2 
7 3.0 ± 0.1 2.6 ± 0.3 1.2 
12 3.3 ± 0.2 3.9 ± 0.2 0.8 
24 0.86 ± 1.2 1.2 ± 0.2 0.7 
29 0.84 ± 1.3 1.3 ± 0.1 0.6 
Impact of Hydrolysis on Biological Activity 
The cytotoxicity of cisplatin,[89–92] is dependent on its 
hydrolysis,[93] however recent computation studies suggest no 
involvement of cis-[Pt(NH3)2(OH2)2]
2+ and cis-
[Pt(NH3)2(OH2)(OH)]
+ in the mode of action of the drug.[94] As 
discussed previously, the modes of action of both NAMI-A and 
KP1019 are thought to be due to the reduction of Ru(III) to 
Ru(II).[24,27] However, ruthenium “piano-stool” complexes with 
ancillary halide ligands have been shown to hydrolyse and bind 
to nucleobases bases,[50,95,96] in which the intermediate is 
thought to be a cationic di-hydrated or mono-hydrated species 
under physiological conditions. The hydrolysis potential has 
been assessed here for both RuCl2L2 and RuI2L2 complexes, in 
which both the di-hydrated or mono-hydrated species could form 
(Scheme 2).[97,98]  
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Scheme 2 Proposed hydrolysis scheme of the bis(picolinamide) ruthenium(III) 
dichloride complexes to cationic mono- and di-aquated intermediates. 
 
 
Compounds 3, 5, 7, 10, 12 and 14 were analysed in aqueous 
solutions as these represent some of the most active ruthenium 
dichloride complexes (7, 12) and some of the least active (5, 10) 
across the cell lines tested. ES-MS analysis of compounds 3, 7 
and 12 were obtained and peaks were detected which can be 
assigned to a di-hydrated species. In contrast, for compounds 5, 
10 and 14, the detected peaks can only tentatively be assigned 
to the mono-hydrated species (Figure S15 and Figure S17). 
UV-Vis spectra were monitored over time to confirm the species 
in aqueous solution. The spectra observed for all RuCl2L2 
compounds show a decrease in Amax in the region of 200320 
nm, and predominantly hypsochromic shifts ranging from 
11414 eV (Table S8). A decrease in Amax is observed in the 
region of 550650 nm which could suggest a MLCT, however 
the spectral peaks are too broad to assign specific 
hypsochromic shifts and charge transfer bands. Therefore, the 
changes observed in all UV-Vis spectra at shorter wavelengths 
have been assigned to intraligand * transitions.[99] ES-MS 
analysis was also obtained for the RuI2L2 compounds 23, 26, 27 
and 28, and the peaks were tentatively assigned to the mono-
hydrated species for all four compounds (Figure S16) and the 
UV-Vis spectra also show changes in the MLCT region but are 
too broad to assign to specific charge transfer bands (Figure 
S9). All compounds show hypochromic nature when monitored 
in aqueous solution over time, which also correlates to a 
decrease in initial concentration of both the RuCl2L2 and RuI2L2 
compounds. The decrease in initial concentration has been 
plotted against time (Figure 11) and shows the largest effects 
for the RuI2L2 compounds, which are the most active against all 
cell lines tested. UV-Vis data also shows isosbestic points, 
suggesting the halide compounds are in equilibrium with a 
possible hydrated species, which is potentially the active 
compound and therefore hydrolysis may be the key to the high 
activities observed for the diiodide compounds.  
Conclusions 
We have presented a library of 31 bis-picolinamide 
ruthenium(III) dihalide complexes, which contain a mixed ligand 
system where one picolinamide ligand is bound (N,N), whilst the 
other is bound (N,O). The RuCl2L2 and RuI2L2 compounds have 
been prepared to allow pairwise comparison of the effects of 
dihalide ligand. X-ray crystallographic analysis has been 
obtained for fifteen of the new compounds, and confirms the 
binding mode of the picolinamide ligand, and that these 
complexes are all in the +3 oxidation state. Some of the RuCl2L2 
complexes were found to co-crystallise with different crystal 
morphologies reflecting their ability to form more than one 
structural isomer and switch isomeric configuration. The cis(X)-
cis(N,N)-cis(N,O), cis(X)-trans(N,N)-cis(N,O) and trans(X)-
trans(N,N)-trans(N,O) arrangements have all been observed. In 
contrast, only a single stable trans(X)-trans(N,N)-trans(N,O) 
Figure 11 Time-dependence formation new species in aqueous solution for 
(a) compounds 3, 5, 7, 10, 12 and 14 in 10% MeOH/90% H2O and (b) 
compounds 23, 26, 27 and 28 in 10% DMF/90% H2O at 293 K 
isomer was obtained for the RuI2L2 complexes. This has been 
confirmed by single crystal X-ray crystallography and powder X-
ray diffraction. The ability to synthesise and purify single isomers 
of the diiodide complexes is very important for the further 
development of these complexes as potential drugs. Through 
knowing the configuration of the active drug and being able to 
synthesise these as single isomers, this eliminates future 
potential isomer-related formulation issues. The library of 
complexes was evaluated against several different human 
cancer cell lines for potential cytotoxic activity. Many of the 
complexes showed significant cytotoxicity with IC50 values 
commonly in the low M range. Activity was both ligand- and 
structure- dependent with several clear structure-activity 
relationships emerging. As exemplified by cisplatin and 
transplatin, historically trans isomers have generally been found 
to be less active than their cis isomers. Interestingly, this study 
identifies picolinamide ruthenium (III) diiodide complexes which 
form a single trans isomer, that are significantly more potent 
than their dichloride analogues which form a mixture of cis and 
trans isomers. For both ruthenium dichloride and ruthenium 
diiodide complexes, enhanced potency was also consistently 
observed when an electron-withdrawing substituent was placed 
in the meta or para position on the picolinamide ligand. 
A preliminary evaluation of the selectivity of these picolinamide 
ruthenium(III) dihalide complexes towards cancer cells versus 
non-cancer cells was undertaken. The ruthenium diiodide 
complexes, as well as being more potent (Table 4) were also 
more selective towards cancer cells than their dichloride 
analogues (Figure 9). For both ruthenium diiodide and 
ruthenium dichloride complexes, substitution of R = 4’-F/Cl/Br 
with R = 2’,4’-diF/diCl/diBr reduced potency, however, these 
substitutions increased cancer selectivity (Figure 10) indicating 
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the importance of assessing both potency and selectivity in 
selection of potential lead compounds for further investigation. 
The picolinamide ruthenium (III) dihalide complexes were 
evaluated for activity against the cisplatin-resistant human 
ovarian cancer cell line A2780cis. Importantly, many of the 
diiodide complexes showed good activity against the cisplatin-
resistant human ovarian cancer cell line A2780cis, with several 
complexes being more potent against cisplatin-resistant A2780 
cancer cells than cisplatin-sensitive A2780 cancer cells. In the 
development of new organometallic anti-cancer drugs, there is a 
need for compounds that are not cross resistant with cisplatin 
and have good selectivity towards cancer cells as opposed to 
normal cells. These studies have identified a number of highly 
potent compounds that have good activity against cisplatin 
resistant A2780 cells and good cancer cell selectivity. Of all the 
compounds tested, complexes 25 and 30 particularly emerge as 
good lead candidates for further evaluation based on their 
potency (Table 4), lack of cross resistance in the cisplatin 
resistant A2780cis cells (Figure 8) and good selectivity towards 
cancer cells compared to normal cells (Figure 10). Studies were 
performed in aqueous solution to gain an understanding of 
hydrolysis steps in the compounds mode of action. UV-Vis and 
ES-MS data suggest the possibility of hydrated species in 
aqueous solution, and the decrease in concentration of the initial 
compounds is most significant for the RuI2L2 compounds. These 
hydrated species are potentially the active species; however, 
further studies are required in order isolate these products and 
understand their effects in vitro. Understanding the mode of 
action of these intermediate species could help to enhance both 
potency and cancer selectivity by tuning compound design.  
Experimental Section 
General 
All complexes are air stable and the reactions were carried out in air. 
Chemicals were obtained from Sigma-Aldrich Chemical Co., Acros 
Organics, Alfa Aesar and Strem Chemical Co., and unless otherwise 
stated were used as supplied. General preparation and characterisation 
data by IR, ES+MS, µeff values and microanalysis for complexes 1 - 31 
are reported here. In addition, general preparation and characterisation 
data for N-Ph-picolinamide ligands are also given. 
Instrumentation 
All NMR spectra were recorded on a Bruker DPX 300 spectrometer, a 
Bruker DRX 500 spectrometer or a Bruker DRX 500 spectrometer. 
Elemental analyses were acquired at the University of Leeds 
Microanalytical Service. Mass Spectra were recorded on a Bruker maXis 
impact mass spectrometer or on a Micromass ZMD spectrometer with 
electrospray ionisation and photoiodide array analyser at the University 
of Leeds Mass Spectrometry Service. Infrared spectra were obtained 
using a Platinum ATR Spectroscopy on a crystal plate with samples 
analysed using OPUS software. Magnetic susceptibilities were measured 
using a Sherwood Scientific Susceptibility at room temperature. 
Elemental Analysis 
All biologically evaluated compounds must demonstrate a purity >95%, 
and so the compounds synthesised within this report have been analysed 
using elemental (CHN) analysis, by a means of combustion. This 
technique requires the sample to be burned in an excess of oxygen and 
has a variety of traps which collect the combustion products: CO2, H2O 
and N2. These masses are then used to help calculated the masses of 
the ‘unknown’ product. The experimental values are compared with the 
calculated values of the sample, and all synthesised compounds herein 
are within 0.5% of the calculated values. 
X-ray crystallographic analysis 
A suitable single crystal was selected and immersed in an inert oil. The 
crystal was then mounted on a glass capillary and attached to a 
goniometer head on a Bruker X8 Apex diffractometer using graphite 
monochromated Mo-K radiation ( = 0.71073 Å) or Agilent SuperNova 
X-ray diffractometer fitted with an Atlas area detector and a kappa-
geometry 4-circle goniometer, using graphite monochromated Mo-Kα 
radiation (λ = 0.71073 Å) or Cu -K, (λ = 1.5418 Å), using 1.0° ϕ-rotation 
frames. The crystal was cooled to 100-150 K by an Oxford Cryostream 
low temperature device.[100] The full data set was recorded and the 
images processed using APEX2[101] or CrysAlis Pro software.[102] 
Structure solution by direct method was achieved through the use of 
SHELXS programs,[103] and the structural model defined by full matrix 
least squares on F2 using SHELX97[104] and SHELXS 2014/7.[105] 
Molecular graphics were plotted using Mercury.[106] Editing of CIFs and 
construction of tables and bond lengths and angles was achieved using 
WC[107] and PLATON,[108] or Olex2 program.[109] Unless otherwise stated, 
hydrogen atoms were placed using idealised geometric positions (with 
free rotation for methyl groups), allowed to move in a “riding model” along 
with the atoms to which they are attached, and refined isotropically. 
SQUEEZE[110] routine was used to remove disordered solvent molecules 
present in complex 7 and 12. 
Cell Line Chemosensitivity Studies 
In vitro chemosensitivity tests were performed by the MTT assay against 
A2780 (human ovarian adenocarcinoma), A2780cis (human ovarian 
cisplatin resistant adenocarcinoma), HT-29 (human colon 
adenocarcinoma) and ARPE-19 non-cancer cell lines. Cells were 
incubated in 96-well plates at a concentration of 2 × 103 cells /well for 24 
hours at 37 °C in an atmosphere of 5% CO2 prior to drug exposure. 
Complexes 1-31 were all dissolved in dimethylsulfoxide and diluted 
further with medium to obtain drug solutions ranging from 250 to 0.49 μM. 
The final dimethylsulfoxide concentration was 0.1% (v/v) which is non-
toxic to cells. Drug solutions or DMSO solvent control were applied to 
cells and incubated for 5 days at 37 °C in an atmosphere of 5% CO2. For 
short drug exposure times, after 1, 3 or 6 h media containing the drug 
was removed and the cells washed twice with PBS before addition of 
fresh complete media for a further 5 days. Cell survival was determined 
using the MTT assay as described.[48] On day 5, MTT (20 µL of a 5 
mg/mL stock) was added to each well and plates were incubated for a 
further 3 hours at 37 °C in an atmosphere of 5% CO2. The solutions were 
then removed and 150 μL of dimethylsulfoxide was added to each well to 
dissolve the purple formazan crystals. A Thermo Scientific Multiskan EX 
microplate spectrophotometer was used to measure the absorbance at 
540 nm. Lanes containing medium only and cells in medium (no drug, 
solvent control) were used as blanks for the spectrophotometer and 
100% cell survival respectively. Cell survival was determined as the 
absorbance of treated cells divided by the absorbance of controls and 
expressed as a percentage. The IC50 values were determined from plots 
of % survival against drug concentration. Each experiment was repeated 
3 times and a mean value obtained. 
Chemosensitivity Under Hypoxic Conditions 
The hypoxia assay was conducted according to the protocol stated 
previously for normoxic conditions. However, during the incubation period, 
the addition of the drug dilutions and the addition of the MTT solution 
were carried out inside a Don Whitley Scientific H35 Hypoxystation which 
was set at 0.1% O2. Drug solutions of complexes and tirapazimine (TPZ) 
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were incubated for 5 days and cell survival was determined using the 
MTT assay as described. 
Hydrolysis Studies 
Samples were prepared by dissolving complexes 3, 5, 7, 10, 12 and 14 in 
10% methanol, and complexes 23, 26, 27 and 28 in 10% DMF, followed 
by the addition of 90% deionised water to give a final concentration of 70 
µM. These aqueous solutions were scanned at various time points by 
UV-Vis Spectrophotometry over 5 days at 293 K. The concentration of 
the complex was determined from a calibration curve or each complex 
taken at a specific wavelength of maximum absorbance to calculate the 
percentage of hydrolysed complex. 
Data Analysis 
Statistical analysis of the results was conducted using Student’s t-test. 
For p-values < 0.05 are considered as significant, and p values < 0.01 as 
very significant. 
N-Ph-picolinamide Ligand Preparation 
The ligands used for complexes 1-10 and 16-26 have been previously 
reported,[19b] and were prepared using the same synthetic route, which is 
a modification of the published procedure by Bhattacharya et al.[19b] The 
yields varied in the range 37-69%. The general procedure of and 
characterisation data of new ligands L11-15 (used for complexes 11-15 
and 27-31) are also provided. 
Functionalised aniline (25 mmol) was added to a solution of pyridine-2-
carboxylic acid (25 mmol) in pyridine (15 ml) and warmed to 50°C for 15 
minutes. To this mixture, triphenylphosphite (25 mmol) was added and 
heated to 110°C for 18 hours yielding an orange solution. Addition of 
water (100 ml) yielded a white paste, to which dichloromethane (40 ml) 
was added and the organic layer separated from the aqueous layer. The 
product in the aqueous layer was extracted with 1:1 (v/v) aqueous HCl (3 
x 100 ml). To neutralise the extract, sodium bicarbonate was added until 
pH 7. The brown solid was isolated by filtration then washed with distilled 
water. After recrystallisation of the product from methanol, washing with 
water and drying in vacuo, yields pale brown needle-like crystals. 
Ligand 11: Yield: 3.48 g, 12.6 mmol, 50%. ES+MS (CHCl3, m/z): 298.98 
[M Na]+. Anal. Found: C 52.0%, H 3.2%, N 10.3%, Br 28.9%. Anal. 
Calc.: C 52.0%, H 3.3%, N 10.1%, Br 28.8%. 1H NMR (CDCl3, 300.13 
MHz, 300K) δ 10.72 (br. s, 1H, CONH), 8.70 (d, 1H, 3J(1H-1H) = 4.7 Hz, 
CH of C5H4N), 8.60 (dd, 1H, 
3J(1H-1H) = 8.3 Hz, 4J(1H-1H) = 1.4 Hz CH of 
C5H4N), 8.32 (d, 1H, 
3J(1H-1H) = 7.8 Hz, CH of C6H4Br), 7.94 (td, 1H, 
3J(1H-1H) = 7.7 Hz, 4J(1H-1H) = 1.7, CH of C5H4N), 7.62 (dd, 1H, 
3J(1H-
1H) = 8.0 Hz, 4J(1H-1H) = 1.3 Hz, CH of C6H4Br), 7.53 (ddd, 1H, 
3J(1H-1H) 
= 7.5 Hz, 4J(1H-1H) = 4.8 Hz, 5J(1H-1H) = 1.6 Hz, CH of C5H4N), 7.40 (m, 
1H, CH of C6H4Br), 7.04 (td, 1H, 
3J(1H-1H) = 7.7 Hz, 4J(1H-1H) = 1.5 Hz, 
CH of C6H4Br). 
13C{1H} NMR (CDCl3, 75.47 MHz, 300 K) δ 162.28 (Q, 
CONH), 149.78 (Q), 148.33 (CH of C5H4N), 137.64 (CH of C5H4N), 
135.94 (Q), 132.49 (CH of C5H4N), 128.37 (CH of C6H4Br), 126.62 (CH of 
C6H4Br), 125.13 (CH of C6H4Br), 122.43 (CH of C6H4Br), 121.41 (CH of 
C5H4N), 113.90 (Q, CBr of C6H4Br). IR (cm
-1): 3288 (m), 3105 (m), 1691 
(s), 1577 (m), 1503 (m), 1462 (w), 1429 (w), 1375 (s), 1294 (s), 1227 (w), 
1146 (w), 1119 (m), 1072 (s), 1038 (s), 997 (s), 890 (m), 857 (m), 822 (s), 
748 (s), 682 (s), 621 (m), 540 (s) 
Ligand 12: Yield: 3.90 g, 14.1 mmol, 56%. ES+MS (CHCl3, m/z): 298.98 
[M Na]+). Anal.Calc.: C 52.0%, H 3.3%, N 10.1%, Br 28.8%. Anal. 
Found: C 52.1%, H 3.2%, N 10.3%, Br 28.5%. 1H NMR (CDCl3, 300.13 
MHz, 300K) δ 10.06 (br. s, 1H, NH), 8.61 (d, 1H, 3J(1H-1H) = 3.6 Hz, CH 
of C5H4N), 8.29 (d, 1H, 
3J(1H-1H) = 7.8 Hz, CH of C5H4N), 8.05 (s, 1H, 
CH of C6H4Br), 7.92 (t, 1H, 
3J(1H-1H) = 7.6 Hz, CH of C5H4N), 7.69 (d, 1H, 
3J(1H-1H) = 7.7 Hz, CH of C6H4Br), 7.5 (dd, 1H, 
3J(1H-1H) = 7.0 Hz, 4J(1H-
1H) = 4.8 Hz, CH of C5H4N), 7.25 (m, 2H, CH of C6H4Br). 
13C{1H} NMR 
(CDCl3, 75.47 MHz, 300 K) δ 161.96 (Q, CONH), 149.37 (Q), 147.93 (CH 
of C5H4N), 139.04 (Q), 137.88 (CH of C5H4N), 130.36 (CH of C6H4Br), 
127.30 (CH of C6H4Br), 126.70 (CH of C5H4N), 122.76 (Q, CBr of 
C6H4Br), 122.61 (CH of C5H4N), 118.15 (CH of C6H4Br). IR (cm
-1): 3335 
(s), 3058 (m), 1698 (s), 1590 (m), 1537 (m), 1483 (m), 1402 (m), 1314 (s), 
1234 (s), 1160 (w), 1125 (m), 1092 (m), 1038 (m), 997 (s), 897 (m), 850 
(s), 810 (m), 769 (s), 661 (s), 587 (s) 
Ligand 13: Yield: 4.78 g, 17.2 mmol, 69%. ES+MS (CHCl3, m/z): 298.98 
[M Na]+). Anal. Found: C 51.8%, H 3.2%, N 10.4%, Br 28.9%. Anal. 
Calc.: C 52.0%, H 3.3%, N 10.1%, Br 28.8%. 1H NMR (CDCl3, 300.13 
MHz, 300K) δ 10.06 (br. s, 1H, NH), 8.63 (d, 1H, 3J(1H-1H) = 4.7 Hz, CH 
of C5H4N), 8.31 (d, 1H, 
3J(1H-1H) = 7.8 Hz, CH of C5H4N), 7.94 (td, 1H, 
3J(1H-1H) = 7.7 Hz, 4J(1H-1H) = 1.7 Hz, CH of C5H4N), 7.71 (d, 2H, 
3J(1H-
1H) = 8.8 Hz, CH of C6H4Br), 7.52 (m, 3H, CH of C5H4N & 2 x CH of 
C6H4Br). 
13C{1H} NMR (CDCl3, 75.47 MHz, 300 K) δ 161.99 (Q, CONH), 
149.51 (Q), 147.98 (CH of C5H4N), 137.79 (CH of C5H4N), 136.85 (Q), 
132.06 (CH of C6H4Br), 126.63 (CH of C5H4N), 122.47 (CH of C5H4N), 
121.21 (CH of C6H4Br), 116.87 (Q, CBr of C6H4Br). IR (cm
-1): 3335 (s), 
3058 (m), 1691 (w), 1590 (w), 1490 (w), 1227 (m), 1186 (w), 1099 (w), 
1038 (w), 997 (m), 816 (m), 688 (m), 614 (s), 506 (s), 486 (m) 
Ligand 14: Yield: 3.83 g, 10.8 mmol, 43%. ES+MS (CHCl3, m/z): 378.9 
[M Na]+). Anal. Found: C 40.6%, H 2.2%, N 7.7%, Br 44.7%.Anal. 
Calc.: C 40.5%, H 2.3%, N 7.9%, Br 44.9%. 1H NMR (CDCl3, 300.13 
MHz, 300K) δ 10.63 (br. s, 1H, NH), 8.60 (d, 1H, 3J(1H-1H) = 4.7 Hz, CH 
of C5H4N), 8.50 (d, 1H, 
3J(1H-1H) = 8.9 Hz, CH of C5H4N), 8.22 (d, 1H, 
3J(1H-1H) = 7.8 Hz, CH of C6H3Br2), 7.86 (td, 1H, 
3J(1H-1H) = 7.7 Hz, 
4J(1H-1H) = 1.7, CH of C5H4N), 7.68 (d, 1H, 
3J(1H-1H) = 2.3 Hz, CH of 
C6H3Br2), 7.44 (m, CH of C5H4N & CH of C6H3Br2). 
13C{1H} NMR (CDCl3, 
75.47 MHz, 300 K) δ 162.31 (Q, CONH), 149.50 (Q), 148.39 (CH of 
C5H4N), 137.76 (CH of C5H4N), 135.24 (Q), 134.68 (CH of C6H3Br2), 
131.43 (CH of C6H3Br2), 126.83 (CH of C5H4N), 122.56 (CH of C6H3Br2), 
122.27 (CH of C5H4N), 116.65 (Q, CBr of C6H3Br2), 114.28 (Q, CBr of 
C6H3Br2). IR (cm
-1): 3288 (m), 3112 (m), 1691 (s), 1563 (m), 1509 (m), 
1456 (w), 1381 (m), 1301 (s), 1234 (w), 1113 (m), 1078 (m), 1038 (s), 
997 (m), 890 (m), 863 (m), 810 (s), 742 (m), 669 (s), 621 (m), 540 (m) 
Ligand 15: Yield: 3.26 g, 9.17 mmol, 37%. ES+MS (CHCl3, m/z): 356.90 
[M H]+. Anal. Found: C 40.6%, H 2.3%, N 7.7%, Br 44.8%. Anal. Calc.: 
C 40.5%, H 2.3%, N 7.9%, Br 44.9%. 1H NMR (CDCl3, 300.13 MHz, 
300K) δ 10.65 (br. s, 1H, NH), 8.82 (d, 1H, 3J(1H-1H) = 2.4 Hz), 8.61 (d, 
1H, 3J(1H-1H) = 4.7 Hz, CH of C5H4N), 8.22 (d, 1H, 
3J(1H-1H) = 7.8 Hz, 
CH of C5H4N), 7.86 (td, 1H, 
3J(1H-1H) = 7.7 Hz, 4J(1H-1H) = 1.7, CH of 
C5H4N), 7.45 (ddd, 1H, 
3J(1H-1H) = 7.6 Hz, 4J(1H-1H) = 4.7 Hz, 5J(1H-1H) 
= 1.2 Hz, CH of C5H4N), 7.38 (d, 1H, 
3J(1H-1H) = 8.6 Hz, He), 7.08 (dd, 
1H, 3J(1H-1H) = 8.5 Hz, 4J(1H-1H) = 2.4 Hz). 13C{1H} NMR (CDCl3, 75.47 
MHz, 300 K) δ 162.31 (Q, CONH), 149.38 (Q), 148.38 (CH of C5H4N), 
137.76 (CH of C5H4N), 137.05 (Q), 133.36 (CH of C6H3Br2), 128.00 (CH 
of C6H3Br2), 126.87 (CH of C5H4N), 124.01 (CH of C6H3Br2), 122.58 (CH 
of C5H4N), 121.25 (Q, CBr of C6H3Br2), 112.21 (Q, CBr of C6H3Br2). IR 
(cm-1): 3301 (s), 3112 (s), 1698 (m), 1570 (m), 1516 (m), 1288 (m), 1227 
(m), 1112 (m), 1018 (s), 870 (s), 803 (s), 742 (s), 675 (s), 580 (m), 500 
(m) 
Preparation of Complexes 1-16 
Functionalised N-phenyl picolinamide (0.80 mmol) was added to a 
solution of RuCl3.3H2O (0.40 mmol) in ethanol (30 mL), followed by 
addition of triethylamine (0.40 mmol). The solution was heated under 
reflux for 2 hours giving a red-orange solution. The volume of solvent 
was reduced by one third to yield an orange solid. The solid was filtered, 
washed with pentane, dried in vacuo and recrystallised via vapor 
diffusion in methanol-pentane yielding red crystals. 
Complex 1: Yield: 0.347 g, 0.60 mmol, 74%. µeff = 1.97 ± 0.12 µβ. 
ES+MS (CH3OH, m/z): 568.0 [M H]
+. Anal. Found: C 46.9; H 3.60; N 
FULL PAPER    
 
 
 
 
 
8.9 %. Anal. Calc.: C 46.4; H 4.0; N 9.0%. IR (cm-1): 3482 (b), 3260 (w), 
3200 (m), 3058 (s), 1617 (b), 1570 (s), 1490 (b), 1449 (b), 1355 (s), 1294 
(s), 1146 (s), 1025 (s), 997 (w), 971 (s), 897 (s), 836 (w), 803 (s), 748 (s), 
688 (s), 587 (s), 506 (s) 
Complex 2: Yield: 0.12 g, 0.20 mmol, 50%. µeff = 1.97 ± 0.12 µβ. ES+MS 
(CH3OH, m/z): 604.0 [M H]
+. Anal. Found: C 45.1; H 3.3; N 8.6%. Anal. 
Calc.: C 45.1; H 3.3; N 8.8%. IR (cm-1): 3489 (b), 3200 (w), 3065 (m), 
1617 (b), 1577 (s), 1496 (s), 1449 (w), 1355 (s), 1301 (s), 1267 (s), 1206 
(s), 1153 (s), 1099 (s), 1031 (s), 964 (s), 917 (s), 863 (s), 755 (s), 682 (s), 
601 (s), 547 (w), 519 (w), 473 (s) 
Complex 3: Yield: 0.13 g, 0.21 mmol, 52%. µeff = 1.83 ± 0.03 µβ. ES+MS 
(CH3OH, m/z): 604.0 [M H]
+. Anal. Found: C 44.4; H 3.1; N 8.4%. Anal. 
Calc.: C 43.9; H 3.5; N 8.5%. IR (cm-1): 3510 (b), 3254 (w), 3220 (w), 
3058 (m), 1624 (b), 1469 (w), 1409 (s), 1348 (s), 1294 (w), 1234 (s), 
1153 (s), 1092 (w), 1058 (w), 1018 (w), 971 (w), 904 (s), 829 (s), 762 (w), 
688 (s), 547 (w), 507 (w), 493 (w) 
Complex 4: Yield: 0.18 g, 0.28 mmol, 72%. µeff = 1.87 ± 0.07 µβ. ES+MS 
(CH3OH, m/z): 640.0 [M H]
+. Anal. Found: C 43.1; H 2.8; N 8.0%. Anal. 
Calc.: C 42.7; H 2.8; N 8.3%. IR (cm-1): 3470 (b), 3220 (w), 3058 (m), 
1611 (b), 1503 (w), 1469 (w), 1429 (w), 1355 (s), 1301 (w), 1260 (w), 
1220 (m), 1139 (s), 1092 (s), 1052 (m), 1031 (m), 964 (s), 924 (m), 850 
(m), 803 (m), 755 (m), 735 (w), 694 (s), 607 (m), 540 (m), 459 (m) 
Complex 5: Yield: 0.07 g, 0.11 mmol, 28%. µeff = 1.96 ± 0.16 µβ. ES+MS 
(CH3OH, m/z): 641.96 [M]
+. Anal. Found: C 43.1; H 3.1; N 8.2%. Anal. 
Calc.: C 42.7; H 2.8; N 8.3%. IR (cm-1): 3482 (b), 3207 (w), 3065 (m), 
1584 (b), 1496 (w), 1341 (m), 1241 (m), 1206 (w), 1173 (s), 1099 (s), 
1058 (w), 978 (s), 924 (w), 870 (m), 762 (s), 688 (s), 587 (w), 506 (w), 
473 (s). 
Complex 6: Yield: 0.15 g, 0.23 mmol, 58%. µeff = 2.21 ± 0.07 µβ. ES+MS 
(CH3OH, m/z): 637.9 [M H]
+. Anal. Found: C 43.4; H 3.1; N 8.1; Cl 
22.1%. Anal. Calc.: C 43.5; H 3.0; N 8.5; Cl 21.4%. IR (cm-1): 3476 (b), 
3220 (w), 3065 (w), 2856 (w), 1590 (b), 1469 (w), 1442 (w), 1341 (m), 
1301 (w), 1260 (w), 1146 (s), 1052 (s), 1031 (m), 964 (m), 924 (s), 850 
(w), 803 (m), 755 (s), 688 (s), 601 (m), 500 (m), 452 (w) 
Complex 7: Yield: 0.15 g, 0.23 mmol, 55%. µeff = 2.40 ± 0.04 µβ. ES+MS 
(CH3OH, m/z): 637.9 [M H]
+. Anal. Found: C 44.0; H 3.2; N 8.3; Cl 
21.5%. Anal. Calc.: C 44.1; H 2.9; N 8.6; Cl 21.7%. IR (cm-1): 3442 (b), 
3254 (w), 3193 (w), 3065 (m), 1597 (b), 1476 (m), 1435 (w), 1391 (s), 
1307 (m), 1260 (m), 1146 (m), 1065 (w), 965 (m), 883 (m), 762 (s), 675 
(s), 594 (w), 513 (w) 
Complex 8: Yield: 0.07 g, 0.11 mmol, 28%. µeff = 2.08 ± 0.03 µβ. ES+MS 
(CH3OH, m/z): 637.9 [M H]
+.. Anal. Found: C 43.2; H 3.0; N 8.1, Cl 
21.8%. Anal. Calc.: C 43.5; H 3.0; N 8.5; Cl 21.47%. IR (cm-1): 3496 (b), 
3247 (w), 3058 (m), 1584 (b), 1490 (m), 1409 (m), 1355 (m), 1294 (m), 
1260 (w), 1241 (w), 1146 (m), 1085 (s), 1052 (w), 1018 (s), 971 (m), 910 
(m), 822 (s), 755 (s), 722 (m), 688 (s), 506 (s), 466 (w) 
Complex 9: Yield: 0.12 g, 0.17 mmol, 44%. µeff = 1.99 ± 0.06 µβ. ES+MS 
(CH3OH, m/z): 705.8 [M H]
+. Anal. Found: C 39.7; H 2.5; N 7.6, Cl 
29.5%. Anal. Calc.: C 39.9; H 2.4; N 7.8; Cl 29.4%. IR (cm-1): 3510 (b), 
3207 (w), 3058 (m), 1590 (b), 1469 (m), 1341 (m), 1301 (w), 1260 (w), 
1146 (m), 1099 (s), 1052 (s), 1025 (w), 964 (w), 917 (m), 857 (m), 803 
(m), 762 (s), 688 (m), 560 (w), 526 (m) 
Complex 10: Yield: 0.11 g, 0.16 mmol, 40%. µeff = 2.53 ± 0.02 µβ. 
ES+MS (CH3OH, m/z): 705.8 [M H]
+. Anal. Found: C 40.6; H 2.9; N 7.5, 
Cl 30.0%. Anal. Calc.: C 40.9; H 2.2; N 7.9; Cl 30.2%. IR (cm-1): 3496 (b), 
3200 (w), 3065 (w), 1577 (b), 1469 (m), 1388 (m), 1334 (m), 1301 (w), 
1260 (w), 1139 (m), 1092 (m), 1052 (m), 964 (m), 931 (m), 890 (w), 863 
(w), 803 (s), 762 (s), 688 (s), 594 (m), 566 (m), 519 (w), 459 (w) 
Complex 11: Yield: 0.13 g, 0.18 mmol, 46%. µeff = 2.02 ± 0.06 µβ. 
ES+MS (CH3OH, m/z): 725.8 [M H]
+. Anal. Found: C 37.6; H 2.6; N 
7.1%. Anal. Calc.: C 37.9; H 2.8; N 7.4%. IR (cm-1): 3496 (b), 3214 (m), 
3065 (m), 1584 (s), 1476 (s), 1442 (w), 1348 (s), 1307 (s), 1260 (m), 
1146 (m), 1052 (s), 971 (w), 924 (s), 843 (w), 810 (m), 748 (s), 688 (m), 
594 (w), 533 (w), 493 (w) 
Complex 12: Yield: 0.19 g, 0.25 mmol, 62%. µeff = 2.05 ± 0.10 µβ. 
ES+MS (CH3OH, m/z): 725.8 [M H]
+
. Anal. Found: C 38.8; H 2.6; N 
7.3%. Anal. Calc.: C 38.8; H 2.6; N 7.5%. IR (cm-1): 3489 (b), 3254 (w), 
3072 (m), 1570 (b), 1476 (s), 1429 (w), 1348 (s), 1294 (m), 1260 (m), 
1146 (m), 1065 (w), 997 (w), 971 (m), 857 (m), 762 (s), 722 (w), 675 (s), 
601 (w), 560 (w), 500 (w) 
Complex 13: Yield: 0.13 g, 0.17 mmol, 44%. µeff = 2.04 ± 0.16 µβ. 
ES+MS (CH3OH, m/z): 725.8 [M H]
+. Anal. Found: C 38.9; H 2.8; N 
7.4%. Anal. Calc.: C 38.8; H 2.6; N 7.5%. IR (cm-1): 3482 (b), 3247 (w), 
3072 (m), 1570 (b), 1490 (m), 1402 (w), 1348 (m), 1288 (m), 1260 (w), 
1146 (m), 1065 (m), 1025 (w), 1004 (s), 964 (w), 910 (w), 822 (s) 755 (s), 
688 (s), 513 (s) 
Complex 14: Yield: 0.19 g, 0.21 mmol, 51%. µeff = 2.10 ± 0.14 µβ. 
ES+MS (CH3OH, m/z): 882.6 [M]. Anal. Found: C 31.8; H 2.1; N 5.9%. 
Anal. Calc.: C 32.0; H 1.9; N 6.2%. IR (cm-1): 3496 (b), 3200 (w), 3065 
(m), 1584 (b), 1462 (m), 1341 (m), 1301 (m), 1260 (m), 1146 (s), 1072 (s), 
1045 (s), 964 (w), 917 (s), 850 (w), 816 (w), 748 (m), 682 (m), 547 (w), 
506 (m) 
Complex 15: Yield: 0.19 g, 0.21 mmol, 54%. µeff = 2.03 ± 0.02 µβ. ES+MS 
(CH3OH, m/z): 882.6 [M]. Anal. Found: C 31.8; H 2.2; N 5.9%. Anal. 
Calc.: C 32.0; H 1.9; N 6.2%. IR (cm-1): 3510 (b), 3186 (w), 3065 (m), 
1584 (b), 1469 (m), 1388 (m), 1334 (m), 1301 (w), 1267 (w), 1146 (s), 
1085 (s), 1031 (s), 971 (m), 931 (m), 870 (m), 810 (m), 755 (s), 694 (s), 
601 (w), 566 (w), 506 (m) 
Complex 16: Yield: 0.09 g, 0.13 mmol, 34%. µeff = 2.01 ± 0.01 µβ. ES+MS 
(CH3OH, m/z): 819.79 [M]. Anal. Found: C 33.3; H 2.2; N 6.2%. Anal. 
Calc.: C 33.7; H 2.5; N 6.6%. IR (cm-1): 3476 (b), 3200 (w), 3051 (m), 
1590 (s), 1556 (s), 1469 (s), 1435 (w), 1341 (m), 1301 (m), 1146 (m), 
1018 (m), 917 (m), 803 (w), 748 (s), 722 (w), 682 (m), 647 (m), 594 (m), 
526 (w), 500(m) 
Preparation of Complexes 17-31 
Functionalised N-phenyl picolinamide (0.80 mmol) was added to a 
solution of RuCl3.3H2O (0.40 mmol) in ethanol (30 mL), followed by 
addition of triethylamine (0.40 mmol). The solution was heated under 
reflux for 2 hours giving a red-orange solution. An excess of KI (4 mmol) 
was added and the solution heated under reflux for 18 hours resulting in 
a dark coloured solution. The solid was filtered, washed with water to 
remove KCl, dried in vacuo and recrystallised via vapour diffusion in 
DMF-ether yielding black/green crystals. 
Complex 17: Yield: 0.26 g, 0.35 mmol, 58%. µeff = 1.68 ± 0.07 µβ. 
ES+MS (DMF, m/z): 751.9 [M H+]. Anal. Found: C 38.8; H 2.7; N 7.3%. 
Anal. Calc.: C 38.4; H 2.6; N 7.5%. IR (cm-1): 3288 (b), 3072 (w), 2856 
(w), 1570 (s), 1483 (m), 1449 (m), 1368 (w), 1294 (w), 1260 (w), 1173 
(w), 1153 (w), 1072 (w), 1025 (w), 903 (w), 755 (s), 694 (s), 587 (m), 513 
(m), 473 (w) 
Complex 18: Yield: 0.22 g, 0.27 mmol, 59%. µeff = 1.71 ± 0.07 µβ. 
ES+MS (DMF, m/z): 787.9 [M H+]. Anal. Found: C 35.2; H 2.2; N 6.6%. 
Anal. Calc.: C 35.1; H 2.6; N 6.8%. IR (cm-1): 3247 (w), 3072 (w), 2883 
(b), 1577 (s), 1490 (m), 1456 (w), 1362 (m), 1301 (w), 1260 (m), 1213 (w), 
1153 (w), 1099 (w), 1025 (w), 964 (w), 910 (w), 863 (w), 789 (m), 748 (s), 
688 (w), 513 (w), 473 (w) 
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Complex 19: Yield: 0.24 g, 0.31 mmol, 58%. µeff = 1.70 ± 0.09 µβ. 
ES+MS (DMF, m/z): 787.8 [M H+]. Anal. Found: C 37.0; H 2.2; N 7.0%. 
Anal. Calc.: C 36.7; H 2.2; N 7.1%. IR (cm-1): 3226 (w), 3072 (w), 2863 
(b), 1584 (m), 1496 (m), 1416 (s), 1375 (w), 1348 (w), 1213 (m), 1153 
(m), 1085 (w), 1011 (w), 971 (w), 910 (w), 836 (m), 762 (m), 675 (m), 540 
(m), 500 (w), 473 (w) 
Complex 20: Yield: 0.17 g, 0.20 mmol, 36%. µeff = 1.83 ± 0.05 µβ. 
ES+MS (DMF, m/z): 823.8 [M H+]. Anal. Found: C 35.1; H 1.8; N 6.6%. 
Anal. Calc.: C 35.1; H 1.8; N 6.8%. IR (cm-1): 3226 (w), 3072 (b), 2883 
(w), 1584 (b), 1503 (m), 1429 (w), 1368 (m), 1253 (m), 1213 (w), 1139 (s), 
1092 (s), 1018 (w), 957 (s), 910 (m), 863 (m), 803 (m), 762 (s), 675 (s), 
601 (s), 573 (w), 533 (s), 473 (m) 
Complex 21: Yield: 0.19 g, 0.24 mmol, 31%. µeff = 1.79 ± 0.04 µβ. 
ES+MS (DMF, m/z): 823.8 [M H+]. Anal. Found: C 35.0; H 1.8; N 6.8%. 
Anal. Calc.: C 35.2; H 1.8; N 6.8%. IR (cm-1): 3214 (w), 3072 (b), 2883 
(w), 1577 (b), 1496 (m), 1355 (m), 1247 (m), 1186 (m), 1132 (m), 1085 
(m), 1058 (w), 971 (s), 917 (m), 876 (m), 803 (m), 762 (s), 694 (m), 668 
(m), 594 (m), 506 (m), 466 (m) 
Complex 22: Yield: 0.29 g, 0.36 mmol, 34%. µeff = 1.77 ± 0.03 µβ. 
ES+MS (DMF, m/z): 819.8 [M]. Anal. Found: C 36.1; H 2.2; N 6.1%. 
Anal. Calc.: C 36.1; H 2.7; N 6.5%. IR (cm-1): 3226 (w), 3072 (b), 2951 
(w), 1563 (s), 1476 (m), 1442 (w), 1355 (m), 1301 (w), 1253 (m), 1153 
(w), 1052 (w), 1031 (w), 964 (w), 917 (w), 748 (s), 688 (m), 634 (w), 533 
(w), 500 (w) 
Complex 23: Yield: 0.21 g, 0.25 mmol, 62%. µeff = 1.60 ± 0.09 µβ. 
ES+MS (DMF, m/z): 841.8 [M Na+]. Anal. Found: C 34.6; H 2.2; N 6.7%. 
Analy. Calc.: C 34.4; H 2.3; N 6.7%. IR (cm-1): 3240 (w), 3065 (b), 2863 
(w), 1563 (s), 1469 (m), 1341 (m), 1301 (w), 1253 (m), 1153 (w), 1072 
(w), 991 (w), 937 (w), 883 (m), 789 (m), 762 (s), 668 (m), 587 (w), 566 
(w), 513 (w), 473 (w) 
Complex 24: Yield: 0.25 g, 0.30 mmol, 60%. µeff = 1.77 ± 0.02 µβ. 
ES+MS (DMF, m/z): 819.8 [M]. Anal. Found: C 36.4; H 2.3; N 6.7%. 
Anal. Calc.: C 36.1; H 2.7; N 6.5%. IR (cm-1): 3254 (w), 3058 (b), 2964 
(w), 1556 (s), 1490 (m), 1355 (w), 1267 (w), 1132 (m), 1085 (m), 1011 
(m), 971 (w), 910 (w), 822 (m), 762 (s), 722 (w), 688 (w), 513 (s), 473 (w) 
Complex 25: Yield: 0.22 g, 0.25 mmol, 44%. µeff = 1.67 ± 0.08 µβ. 
ES+MS (DMF, m/z): 889.7 [M H+]. Anal. Found: C 32.8; H 1.7; N 6.2%. 
Anal. Calc.: C 32.5; H 1.7; N 6.3%. IR (cm-1): 3240 (w), 3065 (w), 2930 
(w), 1550 (m), 1462 (m), 1355 (m), 1267 (w), 1146 (w), 1099 (w), 1058 
(w), 964 (w), 910 (w), 857 (s), 803 (w), 762 (s), 682 (m), 560 (m), 506 (m) 
Complex 26: Yield: 0.32 g, 0.36 mmol, 44%. µeff = 1.76 ± 0.14 µβ. 
ES+MS (DMF, m/z): 887.7 [M]. Anal. Found: C 33.6; H 1.8; N 6.3%. 
Anal. Calc.: C 33.4; H 2.3; N 6.0%. IR (cm-1): 3207 (w), 3079 (w), 2998 
(w), 1537 (b), 1469 (w), 1395 (w), 1355 (w), 1307 (m), 1260 (w), 1152 (s), 
1092 (s), 1052 (s), 1025 (w), 971 (s), 931 (s), 897 (w), 876 (s), 803 (s), 
755 (s), 682 (s), 580 (m), 513 (s), 459 (s) 
Complex 27: Yield: 0.30 g, 0.33 mmol, 52%. µeff = 1.65 ± 0.09 µβ. 
ES+MS (DMF, m/z): 909.7 [M H+]. Anal. Found: C 31.9; H 2.1; N 6.0%. 
Anal. Calc.: C 31.7; H 1.9; N 6.2%. IR (cm-1): 3214 (w), 3051 (w), 2876 
(w), 1570 (m), 1469 (w), 1341 (w), 1301 (w), 1253 (w), 1139 (m), 1031 
(m), 964 (w), 917 (w), 850 (w), 803 (w), 748 (s), 682 (m), 601 (w), 526 
(m), 500 (m) 
Complex 28: Yield: 0.17 g, 0.19 mmol, 50%. µeff = 1.81 ± 0.06 µβ. 
ES+MS (DMF, m/z): 931.7 [M Na+]. Anal. Found: C 31.8; H 1.9; N 6.1%. 
Anal. Calc.: C 31.7; H 1.9; N 6.2%. IR (cm-1): 3260 (w), 3065 (w), 2930 
(w), 1556 (m), 1462 (w), 1341 (w), 1294 (w), 1247 (w), 1146 (w), 1065 
(w), 991 (w), 931 (w), 870 (w), 782 (w), 755 (s), 675 (m), 587 (w), 547 (w), 
473 (w) 
Complex 29: Yield: 0.27 g, 0.30 mmol, 52%. µeff = 1.92 ± 0.05 µβ. 
ES+MS (DMF, m/z): 909.7 [M H+]. Anal. Found: C 31.8; H 1.9; N 5.9%. 
Anal. Calc.: C 31.7; H 1.9; N 6.2%. IR (cm-1): 3247 (w), 3065 (w), 2937 
(w), 1556 (m), 1476 (w), 1355 (w), 1294 (w), 1260 (w), 1227 (w), 1146 
(w), 1065 (w), 1011 (w), 964 (w), 910 (w), 822 (m), 755 (m), 688 (w), 506 
(s)-, 473 (w) 
Complex 30: Yield: 0.34 g, 0.32 mmol, 74%. µeff = 1.68 ± 0.05 µβ. 
ES+MS (DMF, m/z): 1090.5 [M Na+ H+]. Anal. Found: C 28.0; H 1.5; N 
5.2%. Anal. Calc.: C 28.1; H 1.9; N 5.0%. IR (cm-1): 3233 (w), 3065 (w), 
2917 (w), 1550 (m), 1462 (m), 1348 (m), 1260 (w), 1132 (w), 1078 (w), 
1038 (m), 964 (w), 917 (w), 843 (m), 802 (m), 755 (m), 688 (m), 547 (w), 
526 (w), 500 (w) 
Complex 31: Yield: 0.27 g, 0.25 mmol, 33%. µeff = 1.85 ± 0.10 µβ. 
ES+MS (DMF, m/z): 1067.5 [M H+]. Anal. Found: C 27.8; H 1.5; N 5.1%. 
Anal. Calc.: C 28.1; H 1.9; N 5.0%. IR (cm-1): 3207 (w), 3058 (w), 2917 
(w), 1544 (m), 1462 (m), 1388 (m), 1348 (m), 1301 (w), 1146 (m), 1072 
(m), 1025 (s), 964 (w), 931 (w), 870 (w), 803 (w), 755 (m), 688 (m), 607 
(w), 500 (w) 
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This report presents compounds of 
the type RuX2L2, where X = Cl or I and 
L = a functionalised picolinamide 
ligand. The RuCl2L2 complexes exhibit 
a mixture of isomers and are active 
against a range of cancer cell lines. 
Upon a halide exchange reaction to 
the RuI2L2 analogues, a single stable 
trans-iodide isomer is observed. 
These compounds show high 
cytotoxicity in the nanomolar range, 
are cytotoxic under hypoxic conditions 
and selective towards cancerous cells. 
   
Author(s), Corresponding Author(s)* 
Page No. – Page No. 
Title 
 
  
 
 
Layout 2: 
FULL PAPER 
Text for Table of Contents 
 
Author(s), Corresponding Author(s)* 
Page No. – Page No. 
Title 
 
 
 
 
 
 
 
((Insert TOC Graphic here; max. width: 11.5 cm; max. height: 2.5 cm)) 
